Lobbying Information
Subject Matters
- Constitutional Issues
- Consumer Issues
- Environment
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Science and Technology
- Taxation and Finance
Subject Matter Details
Grant, Contribution or Other Financial Benefit
- National Immunization Strategy. Advocacy to seek continued funding in vaccines.
Legislative Proposal, Bill or Resolution
- Canada's Food and Consumer Safety Action Plan proposes a series of initiatives to modernize and strengthen Canada's safety system for food, health and consumer products. Merck Canada seeking to ensure that Canada's safety system for medicines ensures safe and effective medicines for Canadians in a timely manner, consistent with other jurisdictions.
Policies or Program
- Comprehensive Economic Trade Agreement (CETA) negotiations between Canada and European Union: Merck Canada seeking to ensure Canadian intellectual property protection for pharmaceuticals is harmonized with standards in EU to enable Canada to attract innovation.
- Drug Safety and Effectiveness Network (DSEN): Merck Canada seeking to work with DSEN to ensure Canadian standards for safety and effectiveness of drugs consistent with other jurisdictions.
- Health Canada's Blue Print for Renewal: Transforming Canada's Approach to Regulating Health Products and Food to renew the process for approving drugs. Merck Canada seeking to ensure that Canada's safety system for medicines ensures safe and effective medicines for Canadians in a timely manner, consistent with other jurisdictions.
- Patented Medicine Prices Review Board (PMPRB) Pricing Guidelines used by the PMPRB to ensure that prices of patented medicines sold in Canada are not excessive. Merck Canada seeking to ensure PMPRB Guidelines reflect their mandate of ensuring prices are non-excessive, while ensuring an attractive climate for pharmaceutical research.
- The Government's Science and Technology (S&T) Strategy announced in May 2007 which encourages a more competitive Canadian economy and improved quality of life for Canadians through science and technology. Merck Canada seeking to ensure S&T Strategy encourages a more competitive environment for biopharmaceutical innovation in Canada.
- The National Pharmaceutical Strategy as agreed to by First Ministers in 2004, with a focus on options for catastrophic pharmaceutical coverage. Merck Canada seeking to ensure that Canadians' ability to access the medicines they need is increased.
Policies or Program, Regulation
- Canada's Access to Medicine Regime (CAMR) and its Regulations which provide a framework within which eligible developing countries can import less expensive generic versions of patented drugs and medical devices. Merck Canada seeking to ensure that those threatened by serious diseases have timely access to medicines for the diseases and that a research climate that will help to produce cures for other diseases is maintained. Canada's Access to Medicines Regime Regulations.
Regulation
- Health Canada Health Products and Foods Branch Cost Recovery Proposal for Human Drug User Fees. Merck Canada seeking to ensure that renewed user fees adequately fund a safe and efficient review process. Food and Drug Regulation.
- Patented Medicine Prices Review Board (PMPRB) Regulations identifying information to be reported to the PMPRB. Merck Canada seeking to ensure that the information being collected is consistent with PMPRB's mandate to prevent excessive pricing while ensuring an attractive climate for pharmaceutical research.
- Patented Medicines (Notice of Compliance) Regulations which seek to balance patent rights and cost savings. Merck Canada seeking to ensure that patent rights are respected and are internationally competitive.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Federal Office of Regional Development – Quebec (FORD[Q])
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Research Council (NRC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Procurement Review Board of Canada (PRB)
-
Public Health Agency of Canada (PHAC)
-
Public Safety and Emergency Preparedness Canada (PSEPC)
-
Senate of Canada
-
Solicitor General Canada (SGC)
-
Status of Women Canada (SWC)
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Today’s Merck is working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, consumer and animal health products. In Canada, Merck markets over 530 pharmaceutical, consumer and animal health products. Merck is a leader in a broad range of areas such as cardiology, infectious diseases, respiratory, vaccines, women's health and sun care, and is focused on expanding offerings in other areas, including virology, oncology and diabetes.
Merck is one of the top 25 R&D investors in Canada, with an investment of $95.4 million in 2009. Merck has a large manufacturing facility in Québec dedicated to the annual production of some 35 million units of its various brands, including Claritin® and Aerius®. Based in Montréal, Québec, Merck employs over 1600 people across Canada. For more information about our operations in Canada, visit www.merck.ca.
Responsible officer name and position during the period of this registration
Cyril Schiever,
PRESIDENT
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
16711 TransCanada Highway
Kirkland, QC H9H 3L1
Canada
Telephone number:
514-428-2638
Fax number:
514-428-2662
Parent Company Information
- MERCK FROSST COMPANY
-
1959 Upper Water Street
Suite 900
Halifax, NS B3J 2X2
Canada
Subsidiary Beneficiary Information
Merck Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Jeffrey Malawski,
National Manager, Public Health |
No public offices held
- Patricia Massetti,
Vice President, Public Affairs & Patient Access |
No public offices held
- Cyril Schiever,
President |
No public offices held
- Sandra Wainwright,
Director - Regulatory Affairs |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Kathy Armstrong,
Manager, Patient Access - Ontario |
No public offices held
- Christian Blouin,
Director, Public Health & Government Relations |
No public offices held
- Robert Livingston,
Director, Federal Government Affairs |
No public offices held
- Wendy Morton,
Manager, Policy - Health |
No public offices held
